Effect of Granulocyte-Colony Stimulating Factor on Endothelial Cells and Osteoblasts by LIU, XL et al.
Title Effect of Granulocyte-Colony Stimulating Factor on EndothelialCells and Osteoblasts
Author(s) LIU, XL; HU, X; CAI, WX; Lu, WW; Zheng, L
Citation BioMed Research International, 2016, v. 2016, p. 8485721:1-8
Issued Date 2016
URL http://hdl.handle.net/10722/234463
Rights This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Research Article
Effect of Granulocyte-Colony Stimulating Factor on
Endothelial Cells and Osteoblasts
Xi Ling Liu,1 Xiang Hu,1 Wei Xin Cai,2,3 Weijia William Lu,4 and Li Wu Zheng1
1Discipline of Oral Diagnosis and Polyclinics, Faculty of Dentistry, The University of Hong Kong, Hong Kong
2Discipline of Oral and Maxillofacial Surgery, Faculty of Dentistry, The University of Hong Kong, Hong Kong
3Department of Oral and Maxillofacial Surgery, Guanghua School and Research Institute of Stomatology,
Sun Yat-sen University, Guangzhou 510000, China
4Department of Orthopedics and Traumatology, The University of Hong Kong, Hong Kong
Correspondence should be addressed to Li Wu Zheng; lwzheng@hku.hk
Received 10 November 2015; Revised 28 January 2016; Accepted 31 January 2016
Academic Editor: Alessandro Isidori
Copyright © 2016 Xi Ling Liu et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objectives. Some animal studies showed that granulocyte-colony stimulating factor (G-CSF) provides beneficial environment for
bone healing. It has been well documented that endothelial cells and osteoblasts play critical roles in multiple phases of bone
healing. However, the biological effects of G-CSF on these cells remain controversial. This study aimed to investigate the influence
of G-CSF at various concentrations on endothelial cells and osteoblasts.Materials and Methods. Human umbilical vein endothelial
cells (HUVECs) and human osteoblasts (hOBs) were treated with G-CSF at 1000, 100, 10, and 0 ng/mL, respectively. The capacity
of cell proliferation, migration, and tube formation of HUVECs was evaluated at 72, 8, and 6 hours after treatment, respectively.
The capacity of proliferation, differentiation, and mineralization of hOBs was evaluated at 24 hours, 72 hours, and 21 days after
treatment, respectively. Results. HUVECs treated with 100 and 1000 ng/mL G-CSF showed a significantly higher value comparing
with controls in migration assay (𝑝 < 0.001, 𝑝 < 0.01, resp.); the group treated with 1000 ng/mL G-CSF showed a significantly
lower value on tube formation. No significant difference was detected in groups of hOBs. Conclusions. G-CSF showed favorable
effects only on the migration of HUVECs, and no direct influence was found on hOBs.
1. Introduction
Angiogenesis and osteogenesis are two interdependent activ-
ities which play crucial roles during bone development
and regeneration [1]. Angiogenesis is the formation of new
blood vessels occurring in an adult through migration and
proliferation and tubular structures formation of endothelial
cells. Osteogenesis takes place near newly formed vessels that
mediate delivery of osteoprogenitor cells, secrete mitogens
for osteoblasts, and transport nutrients and oxygen. In bone,
vascular development always precedes osteogenesis [1, 2].
During skeletal development and fracture repair, the
coordination of multiple events, such as migration, differ-
entiation, and activation of multiple cell types and tissues,
is required. Endothelial cells and osteoblasts are two of the
major cell types involved in the process of bone regeneration.
The endothelial cells make up the inner surface of the
microvascular or blood vessels which supply the surrounding
cells with oxygen and nutrients and remove waste products.
The development of a microvasculature andmicrocirculation
is critical for the homeostasis and regeneration of living
bone, without which the tissue would simply degenerate
and die [3]. Inadequate bone vascularity is associated with
decreased bone formation and bone mass. Compromise of
angiogenesis during fracture repair usually results in the
formation of fibrous tissue. Under the circumstance of a well-
developed network, the osteoblasts produce osteoid, calcify
and differentiate to osteocytes, and exhibit healthy bone
formation. A poor blood supply is therefore considered as
a risk factor for an impaired bone healing. Factors that can
stimulate the activity of endothelial cells (angiogenesis) as
well as that of osteoblasts (bone formation) are likely to have
a clear advantage to enhance bone repair.
Granulocyte-colony stimulating factor (G-CSF) is a clin-
ical available growth factor, which stimulates the production
of white blood cells, particularly granulocytes [4]. G-CSF
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alsomobilizes hematopoietic stem cells into peripheral blood
[4]. G-CSF has been shown to promote bone repair in
animal models. It was suggested that locally applied G-SCF
contributes to an ideal local environment for bone healing by
supplying adequate blood flow and stimulating osteogenesis
[5]. However, the effect of G-CSF on endothelial cells and
osteoblast are rarely investigated, and the results remain
controversial. Bussolino et al. found that G-CSF was capable
of inducing the migration and proliferation of endothelial
cells at 100 ng/mL [6], while Lee et al. reported that G-
CSF promotes endothelial migration and tube formation at
a low dose, though no effect was found on proliferation [7].
Christopher and Link suggested that long-term systematic
administration of G-CSF induced apoptosis in osteoblast and
inhibited its differentiation in vivo [8].
In this study, to further understand the effect of G-CSF on
endothelial cells and osteoblasts, we tested G-CSF at various
doses on human umbilical vein endothelial cells and human
osteoblasts.
2. Materials and Methods
2.1. Reagents. Recombinant human G-CSF (rhG-CSF) pur-
chased from GIBCO® Invitrogen (Camarillo, CA, USA) was
prepared according to manufactures instruction. Human
umbilical vein endothelial cells (HUVECs), endothelial cell
medium (ECM), human osteoblasts (hOBs), and osteoblast
medium (ObM) were purchased from ScienCell Research
Laboratories (San Diego, CA, USA).
2.2. HUVECs
2.2.1. Culture of HUVECs. HUVECs were cultured in ECM
at 37∘C with 5% CO
2
. Passages three to six were used in all
experiments.
2.2.2. Proliferation Assays. To assess the influence of rhG-
CSF on HUVECs growth, MTT [3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide] cell proliferation assay
was performed. All samples were run in triplicate in 48-well
plates. Briefly, HUVECs were plated at 2 × 103 cells/well and
grown 24 hours in ECM.Mediumwas subsequently removed
and replaced with ECM, or ECM with rhG-CSF at 10 ng/mL,
100 ng/mL, or 1000 ng/mL. The cells were incubated for
72 hours. Then medium was removed and rinsed with
phosphate-buffered saline. MTT dye solution was added and
cellswere incubated at 37∘C.After 4 hours, SDS-HCL solution
was added and kept in incubator at 37∘C overnight. Cells
were then subjected to a spectrophotometer (SpectraMaxM2,
Sunnyvale, CA, USA) for measurement (𝜆 = 570 nm). Level
of proliferation of HUVECs was calculated as follows:
Proliferation [%] =
(Absorbance in tested sample) − (Absorbance in negative control)
(Absorbance in control) − (Absorbance in negative control)
× 100%, (1)
where “control” denotes cells without any additives and
“negative control” means an empty well without cell [9, 10].
2.2.3. Wound Healing Assay. To assess the effects of rhG-CSF
on the migration ability of HUVECs, wound healing assay
was conducted as described by Lamet al. [9]. All sampleswere
run in triplicate in 24-well plates. HUVECs were seeded at 1.5
× 104 cells/well with ECM and incubated overnight at 37∘C
with 5% CO
2
. After incubation, cells were then starved for
24 hours by low serum (0.5% FBS). Then monolayers were
horizontally scratched using a P100 pipette tip to create the
wound. Cells were washed with phosphate-buffered saline
to remove the debris. ECM alone or ECM with rhG-CSF at
10 ng/mL, 100 ng/mL, or 1000 ng/mL was added to allow for
wound healing. Immediately after the change of medium,
three randomly selected views along the scraped line were
photographed on each well at 50x magnifications. After 8
hours of incubation, another set of images was taken using
the same method.
Image analysis for signs of migration was performed
using LeicaQwin Image Processing&Analysis SoftwareV.2.6
(Leica, Cambridge, UK). The increment of migration was
calculated by subtracting the length of scraped line at 8 hours
from that of 0 hours. A reduction in the scraped area indicates
a sign of migration.
2.2.4. Tube Formation Assay. The effects of rhG-CSF on
HUVEC differentiation were examined by in vitro tube for-
mation on growth factor reduced Matrigel matrix (BD Bio-
sciences, Franklin lakes, NJ). Matrigel solution was thawed
overnight at 4∘C, and all plasticware was precooled at −20∘C.
Resuspended HUVECs in ECM alone or ECM with rhG-
CSF at 10 ng/mL, 100 ng/mL, or 1000 ng/mL were plated (1.5
× 104/well) on growth factor reduced Matrigel (60 𝜇L/well)
in a 96-well tissue culture-treated plate, as suggested by
Arnaoutova et al. [11]. All samples were run in triplicate.
After 6 hours of incubation at 37∘C in humidified air with 5%
CO
2
, endothelial network formation was examined. Images
were taken at randomly chosen fields in each well at 100x
magnifications.Themean value of total tubule length in each
group was quantified by Leica Qwin Image Processing &
Analysis Software V.2.6 (Leica, Cambridge, UK). Tube-like
structures were defined as endothelial cord formations that
were connected at both ends [9].
2.3. hOBs
2.3.1. Cultures of hOBs. hOBs were cultured in ObM and
incubated at 37∘C with 5% CO
2
. Passages three to six were
used in all experiments.
2.3.2. ProliferationAssays. To assess the influence of rhG-CSF
on hOBs growth, MTT cell proliferation assay was adopted.
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All samples were run in triplicate in 48-well plate. Briefly,
2 × 103 cells were plated and grown for 24 hours in ObM.
Medium was then removed and replaced with ObM, or ObM
with rhG-CSF at 10 ng/mL, 100 ng/mL, or 1000 ng/mL. The
cells were incubated for 72 hours.Thenmediumwas removed
and rinsed with PBS. MTT dye solution was added and cells
were incubated at 37∘C. After 4 hours, SDS-HCL solution
was added and kept in incubator at 37∘C overnight. Cells
were then subjected to a spectrophotometer (SpectraMax
M2, Sunnyvale, CA, USA) for measurement (𝜆 = 570 nm).
Level of proliferation of hOBs was calculated as described
previously in Section 2.2.
2.3.3. Differentiation Assay. Alkaline phosphatase (ALP)
activity was evaluated as an early marker for osteogenic dif-
ferentiation. Briefly, hOBs were treated with control medium
and different dosages of rhG-CSF, and then ALP released
in the medium was examined. All samples were run in
triplicate in 24-well plate. Cells were plated at a density of
2 × 104 cells/well. After overnight incubation, medium was
changed with ObM alone or ObM with rhG-CSF added
at concentrations of 10 ng/mL, 100 ng/mL, and 1000 ng/mL.
After 72 hours of incubation, the cultures were rinsed twice
with ice-cold PBS, solubilized in Tris/glycin/Triton buffer.
ALP released in the medium after 72 h after treatment
was assayed utilizing the p-nitrophenyl phosphate (pNPP)
ALP assay kit according to the manufacturer’s introduction
(AnaSpec, Fremont, CA, USA). The colour change was mea-
sured spectrophotometrically at 405 nm (SpectraMax M2,
CA, USA). The ALP released by the cells was normalized per
microgram of cell protein. Protein content was measured in
cell lysate by bicinchoninic acid (BCA) protein assay reagent
kit (Pierce Biotechnology, Rockford, IL, USA) [12].
2.3.4. Mineralization Assay. Mineralization of the extracellu-
larmatrixwas used as a latemarker of in vitro bone formation.
All samples were run in triplicate in 24-well plates. hOBs
were seeded at 4 × 104 cells/well and cultured in ObM. After
24 hours, medium was switched to calcification medium
[ObM also containing 10mM 𝛽-glycero phosphate (Sigma)
and 50mg/mLL-ascorbic acid (Sigma)] alone, or calcification
medium with rhG-CSF added at concentrations of 10 ng/mL,
100 ng/mL, or 1000 ng/mL. The medium in each group was
replaced every 4 days. Cells cultured in calcification medium
have been used as a basal control. After an incubation period
of 21 days, the mineralized matrix was stained for calcium
by Alizarin-red (ARS) staining. The cultures were fixed by
covering with 4% paraformaldehyde and incubated at room
temperature for 15 minutes. After rinsing with distilled water
3 times, ARS solution was added and incubated at room
temperature for 20 minutes. The excess dye was removed by
washing 4 times with deionized water. Then, 1mL of water
was added to each well to prevent the cells from drying,
and the images were acquired. To quantify the ARS staining,
10% acetic acid was added to each well and incubated for 30
minutes. Then, the cells and acetic acid were vortexed for 30
seconds and heated to 85∘C for 10 minutes. After cooling,
the slurry was centrifuged at 20,000 g for 15 minutes, and the
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Figure 1: Effect of rhG-CSF on the proliferation of HUVECs. The
amount of cells was determined using theMTT assay as described in
Section 2. Results are expressed as percentages of the control group.
The data shown are presented as mean ± SE.
supernatant was collected.The standard/sample was added to
a transparent-bottom 96-well plate, and optical density was
measured at 405 nm with spectrophotometry.
2.4. Statistics. Normality and homogeneity of variance were
checked. One-way ANOVA was performed to determine the
levels of significant differences with Bonferroni post hoc tests
(SPSS V.20). All statistical tests adopted significance level of
𝑝 < 0.05.
3. Results
3.1. Effect of rhG-CSF on HUVECs
3.1.1. Cell Proliferation. All three treatment groups showed
a slightly lower proliferation rate than the control group
(Figure 1). No significant differences were found.
3.1.2. Cell Migration. The effect of rhG-CSF on cell migra-
tion of HUVECs was determined by wound healing assay
(Figure 2). At 8 hours after scratch, little migration was
observed in the control group, whereas an obvious increment
inmigrationwas found in all treatment groups.With the raise
in dosage of rhG-CSF, the increment of migration appeared
to be bell-shaped. In the group treated with 100 ng/mL and
1000 ng/mL of rhG-CSF, significantly higher values of cell
migration than of the control group were found (𝑝 < 0.001
and 𝑝 < 0.01, resp.).
3.1.3. Tube Formation. The processes of angiogenesis typi-
cally consist of proliferation and alignment to form tubular
structures [11]. To test the ability of rhG-CSF on the induction
of capillary tube formation, a tube formationmodel was used
by culturing HUVECs on growth factor reduced Matrigel
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Figure 2: Effect of rhG-CSF on cell migration of cultured HUVECs. (a) Wound healing assay. Representative images of wound healing at
the beginning (0 hours) and 8 hours after wound scratch. (b)The level of cell migration into the wound scratch was quantified by measuring
the wound healing distance. Scale bar represents 500𝜇m.The data shown are presented as mean ± SE. ∗∗ denotes 𝑝 < 0.001, and ∗ denotes
𝑝 < 0.01.
(Figure 3). Among the four groups, the groups treated with 10
and 100 ng/mL rhG-CSF showed similar values as the control
group, with the 100 ng/mL group demonstrating a slightly
higher value, but no statistical difference was detected, while
the 1000 ng/mL rhG-CSF group showed significantly lower
value in total tube length than the control group (𝑝 < 0.01),
indicating compromised ability of tube formation.
3.2. Effect of rhG-CSF on hOBs
3.2.1. Cell Proliferation. hOBs treated with 1000 ng/mL rhG-
CSF showed similar proliferation rate as the control group,
while the other two groups showed slightly lower rates
(Figure 4). No significant differences were found between
rhG-CSF treated groups and the control group.
3.2.2. Cell Differentiation. Seventy-two hours after treatment,
the 10 and 100 ng/mL rhG-CSF groups showed slightly higher
value of ALP when compared to the control group, while the
value in the group of 1000 ng/mL rhG-CSF group was lower
(Figure 5). No statistical difference was detected between
rhG-CSF treated groups and the control group.
3.2.3. Cell Mineralization. A quantitative ARS method was
performed to detect calcium compounds deposited in the
extracellular matrix as a result of mineralization. After 21-day
culture in the presence of osteogenic supplements, no obvious
difference of staining was observed between groups. The
rhG-CSF groups showed slightly higher absorbance than the
control group, with no statistical difference detected between
rhG-CSF treated groups and the control group (Figure 6).
4. Discussion
G-CSF has been widely used tomobilize CD34+HSCs and to
increase circulating granulocytes in patients receiving bone
marrow transplantation or chemotherapy [13]. It is reported
that G-CSF showed the effect of recruiting HSCs and the
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Figure 3: Effect of rhG-CSF on tube formation of cultured HUVECs. (a) Tube formation assay. Representative images of cultured HUVECs
after incubation for 6 hours, onMatrigel-coating with rhG-CSF at indicated concentrations. (b)The length of total tube length was quantified.
The data shown are presented as mean ± SE. Scale bar represents 200 𝜇m. ∗ denotes 𝑝 < 0.01.
other lineage cells—EPCs, facilitating postnatal tissue regen-
eration in the cardiovascular system [14]. Both in animal
models and in clinical trials, G-CSF has demonstrated its
angiogenic potentials as a growth factor used for stem and
progenitor cell mobilization in malignant and nonmalignant
disease [15, 16]. Therefore, G-CSF administration has been
considered as a promising method for therapeutic angiogen-
esis.
Early in the 1990s, in vitro studies have shown that G-
CSF (100 ng/mL) had direct stimulatory actions on mature
vascular endothelial cells, by showing positive effect on cell
migration, proliferation in culture, and capillary-like tube
formation on Matrigel culture in vitro [6]. A recent study
has demonstrated that G-CSF are capable of enhancing
the expression of multiple cell cycle proteins of endothelial
cells and preventing cell death by increasing cell viability,
decreasing apoptosis and caspase-3 activity [17]. Besides the
potential of G-CSF on angiogenesis, recent studies have
further demonstrated its ability of mobilizing mesenchymal
stem cells (MSC), from which osteoblasts were derived, into
peripheral blood [18]. An animal study also demonstrated its
potential in bone regeneration by supplying adequate blood
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Figure 4: Effect of rhG-CSF on the proliferation of hOBs. The
number of cells was determined using theMTT assay as described in
Section 2. Results are expressed as percentages of the control group.
The data shown are presented as mean ± SE.
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Figure 5: Assessment of ALP activity of hOBs at 72 hours after
treatment. Results are expressed as 𝜇M/𝜇g protein. The data shown
are presented as mean ± SE.
flow and stimulating osteogenesis through local administra-
tion [5].These findings suggest that by local administration of
lower doses, G-CSFmay provide a beneficial environment for
angiogenesis and osteogenesis.However, controversial results
are also reported. In an in vitro study, Tura et al. reported
that G-CSF at 100 ng/mL exhibited an inhibitory effect on
tube formation inHVUECs [19]. Another study reported that
G-CSF induced osteoblast apoptosis and inhibited osteoblast
differentiation in rat, when administrated systematically at a
relatively high dose (250 𝜇g/kg per day, for 7 days) [8].
To clarify the effect of different dosages of G-CSF on
endothelial cells and osteoblasts, the present study evaluated
the influence of G-CSF on HUVECs and hOBs of three
concentrations.
The angiogenic process of endothelial cells involves cell
proliferation, migration, alignment, and tube formation [20].
In earlier studies, Bussolino et al. demonstrated that G-CSF
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Figure 6: ARS staining of hOBs at 21 days of osteogenic differentia-
tion. ARS acid extraction was used to semiquantify the production
of mineral by hOBs. The data shown are presented as mean ± SE.
at low dosage (10 and 100 ng/mL) stimulated angiogenic
functions of mature endothelial cells, resulting in enhanced
migration, proliferation, and tube formation in vitro [6].
However, in our study, G-CSF showed no positive effect on
proliferation of HUVECs regardless of the dosage, which
is consistent with the result of Lee et al. and Stasˇko et
al. [7, 21]. In wound healing assay, we found a significant
enhancement on cell migration in cells treated with G-CSF
at 100 ng/mL and 1000 ng/mL compared to the other group.
Our findings demonstrate that G-CSF is capable of inducing
migration of mature human endothelial cells. Proliferation
and migration are both important early signs of angiogenesis
of endothelial cells. The discrepancy found in proliferation
assay compared with Bussolino et al. may be a result of the
application of different derivatives of rhG-CSF [6]. As it is
reported there were about one hundred derivatives of rhG-
CSF created by various gene mutation techniques, and two
different derivatives of rhG-CSF could result differently in cell
proliferation assay [22].
Based on the differentiation of endothelial cells, tube
formation assay replicates many steps in angiogenic process,
including cell adhesion, migration, protease activity, align-
ment, and tube formation [11]. It has been reported that
low concentration of G-CSF demonstrated a favorable effect
on proliferation and migration through certain pathways
[17, 23]. However, the mechanism of the interaction during
tube formation remains unclear. In the tube formation
assay, we found that 100 ng/mL of G-CSF showed higher
value in the total tube length than the other groups, while
1000 ng/mL of G-CSF showed a significant lower value when
compared to the control group, indicating an inhibitory effect
on angiogenesis. It would be interesting to further explore
the underlying mechanism of the inhibition effect at high
concentration in tube formation process.
The role of osteoblast in bone tissue regeneration is char-
acterized by three sequential stages: proliferation, differenti-
ation, and mineralization of the extracellular matrix, which
indicates the endpoint of osteoblast phenotypic expression
[24]. To evaluate the three stages in osteogenesis, proliferation
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assay, ALP, and ARS test were performed on hOBs. The
results showed that G-CSF had little effect on the prolifera-
tion and differentiation on hOBs. Though the values of G-
CSF groups in the ARS staining test were slightly higher
than that of the control group, no statistic differences were
detected, and no dose-dependent tendency was observed.
These results indicate that G-CSF alone may have limited
effect on hOBs. Moreover, there have been controversies
regarding the effect of G-CSF on osteoblasts under different
environment. It was reported that under normal condition,
a high dose of daily injection of G-CSF (250 𝜇g/kg per
day, for 7 days) induced osteoblasts apoptosis and inhibited
osteoblasts differentiation in a mouse model [8]. However,
under fracture environment, a local administration of G-CSF
at low dosage (5 𝜇g/rabbit) mobilized more osteoblasts into
the defect area and resulted in enhanced osteogenesis [5].
Bone regeneration, especially during bone reconstruction, is
a complex process that involves a large number of growth
factors and cytokines for its regulation. In the present study,
the results suggested that the effect of G-CSF on hOBs may
not totally depend on the direct local effect.
5. Conclusion
In conclusion, these findings indicated that when applied
at 100 ng/mL in HUVECs, G-CSF significantly stimulated
the cell migration, which was a crucial process during
angiogenesis. However, G-CSF showed little direct effect on
hOBs regardless of the concentration. Further investigation
is needed to evaluate a detailed mechanism, such as how
high concentration of G-CSF inhibits the tube formation of
HUVECs and how hOBs is stimulated by G-CSF.
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